Literature DB >> 4426258

[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

H Stickl, V Hochstein-Mintzel, A Mayr, H C Huber, H Schäfer, A Holzner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4426258     DOI： 10.1055/s-0028-1108143

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN： 0012-0472            Impact factor:   0.628


× No keyword cloud information.
  92 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus.

Authors:  Justin J Pollara; April H Spesock; David J Pickup; Scott M Laster; Ian T D Petty
Journal:  Virology       Date:  2012-04-23       Impact factor: 3.616

4.  Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.

Authors:  U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

5.  Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.

Authors:  Graham J Hatch; Victoria A Graham; Kevin R Bewley; Julia A Tree; Mike Dennis; Irene Taylor; Simon G P Funnell; Simon R Bate; Kimberley Steeds; Thomas Tipton; Thomas Bean; Laura Hudson; Deborah J Atkinson; Gemma McLuckie; Melanie Charlwood; Allen D G Roberts; Julia Vipond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

6.  Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain.

Authors:  F Scheiflinger; F G Falkner; F Dorner
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 8.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

9.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

10.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.